Corporate Profile

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit

Contact Pacira Investor Relations

For investor relations inquiries, please contact
Susan Mesco
(973) 451-4030

Stock Quote

NASDAQ: PCRXData as of 04/24/199:30 a.m. ET
39.14USD - 0.01 (0.03%)
Volume | 2,333

refresh Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
View Our Latest Investor Presentation

Receive Email Alerts from Pacira

Sign up here to receive alerts

Sign up to automatically receive free Pacira Pharmaceuticals, Inc. financial information by email. Once signed up, you may choose from the following options:

  • Pacira BioSciences, Inc. SEC Filings Alert
  • Pacira BioSciences, Inc. News Alert

You may change your email options at any time, or opt out if desired.